[Can vasomotion be modified by vasoactive substances or hemodilution?].
The maintenance of adequate local tissue perfusion is the result of control mechanisms which reside at the level of microscopic blood vessels: The constriction and relaxation of the vessels whose vascular walls are endowed with smooth muscle. This phenomenon of vasomotion guarantees homeostatic conditions in peripheral tissues. Superior disorders of homeostasis are primarily compensated by activating the vasomotion. The increase of vasomotion results in prostration of the vasomotoric activity and ends in the local biological disaster finally. Therefore an essential therapeutic strategy to avoid or remove peripheral arterial reduced or lacking perfusion is the reactivation of vasomotion. In this pilot study the effect of conservative therapeutic strategies to the vasomotion was investigated with dynamic capillaroscopy in normal perfused areas of the finger nailfold. A significant influence of buflomedil and alprostadil to the capillary blood cell velocity was found. Vasomotion was susceptible to hydroxyethylstarch and alprostadil but was influenced significantly only by buflomedil. Nevertheless we cannot conclude that the applicated substances will have a favourable effect in ischemic areas too, where maximum dilatation still exists.
Tischler
R
R
Klinischen Abteilung für Angiologie, Medizinischen Universitätsklinik Graz.
Decrinis
M
M
Skursky-Roller
R
R
D000527:Alprostadil / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D002196:Capillaries / Q000187:drug effects / Q000503:physiopathology; D003131:Combined Modality Therapy; D005260:Female; D006438:Hemodilution; D006801:Humans; D007511:Ischemia / Q000188:drug therapy / Q000503:physiopathology; D007866:Leg / Q000098:blood supply; D008297:Male; D009262:Nails / Q000098:blood supply*; D011759:Pyrrolidines / Q000627:therapeutic use*; D014655:Vascular Resistance / Q000187:drug effects* / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use*
D011759:Pyrrolidines; D014665:Vasodilator Agents; D000527:Alprostadil; C010651:buflomedil